{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T13:13:01Z","timestamp":1786194781352,"version":"build-2736575974"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cannabis Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The use of cannabidiol (CBD) for therapeutic purposes is receiving considerable attention, with speculation that CBD can be useful in a wide range of conditions. Only one product, a purified form of plant-derived CBD in solution (Epidiolex), is approved for the treatment of seizures in patients with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. Appraisal of the therapeutic evidence base for CBD is complicated by the fact that CBD products sometimes have additional phytochemicals (like tetrahydrocannabinol (THC)) present, which can make the identification of the active pharmaceutical ingredient (API) in positive studies difficult. The aim of the present review is to critically review clinical studies using purified CBD products only, in order to establish the upcoming indications for which purified CBD might be beneficial. The areas in which there is the most clinical evidence to support the use of CBD are in the treatment of anxiety (positive data in 7 uncontrolled studies and 17 randomised controlled trials (RCTs)), psychosis and schizophrenia (positive data in 1 uncontrolled study and 8 RCTs), PTSD (positive data in 2 uncontrolled studies and 4 RCTs) and substance abuse (positive data in 2 uncontrolled studies and 3 RCTs). Seven uncontrolled studies support the use of CBD to improve sleep quality, but this has only been verified in one small RCT. Limited evidence supports the use of CBD for the treatment of Parkinson\u2019s (3 positive uncontrolled studies and 2 positive RCTs), autism (3 positive RCTs), smoking cessation (2 positive RCTs), graft-versus-host disease and intestinal permeability (1 positive RCT each). Current RCT evidence does not support the use of purified oral CBD in pain (at least as an acute analgesic) or for the treatment of COVID symptoms, cancer, Huntington\u2019s or type 2 diabetes. In conclusion, published clinical evidence does support the use of purified CBD in multiple indications beyond epilepsy. However, the evidence base is limited by the number of trials only investigating the acute effects of CBD, testing CBD in healthy volunteers, or in very small patient numbers. Large confirmatory phase 3 trials are required in all indications.\n<\/jats:p>","DOI":"10.1186\/s42238-023-00186-9","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T09:02:11Z","timestamp":1686646931000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["The therapeutic potential of purified cannabidiol"],"prefix":"10.1186","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1672-6610","authenticated-orcid":false,"given":"Saoirse Elizabeth","family":"O\u2019Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne Skov","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitte Nykjaer","family":"Nikolajsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi Ziegler","family":"Bruun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhenu","family":"Bhuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hoeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"186_CR1","unstructured":"YouGov. report on CBD (CBD.xls (yougov.com))."},{"key":"186_CR2","unstructured":"FSA CBD. recommendation (Cannabidiol (CBD) | Food Standards Agency)."},{"key":"186_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1089\/can.2018.0006","volume":"3","author":"J Corroon","year":"2018","unstructured":"Corroon J, Phillips JA. A cross-sectional study of Cannabidiol users. Cannabis Cannabinoid Res. 2018;3:152\u201361. https:\/\/doi.org\/10.1089\/can.2018.0006.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"10","key":"186_CR4","doi-asserted-by":"publisher","first-page":"e2020977","DOI":"10.1001\/jamanetworkopen.2020.20977","volume":"3","author":"EC Leas","year":"2020","unstructured":"Leas EC, Hendrickson EM, Nobles AL, Todd R, Smith DM, Dredze M, et al. Self-reported cannabidiol (CBD) use for conditions with proven therapies. JAMA Netw Open. 2020;3(10):e2020977.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"186_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/S42238-021-00061-5","volume":"3","author":"J Moltke","year":"2021","unstructured":"Moltke J, Hindocha C. Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems. J Cannabis Res. 2021;3(1):5. https:\/\/doi.org\/10.1186\/S42238-021-00061-5.","journal-title":"J Cannabis Res"},{"key":"186_CR6","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","volume":"78","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, del Giovane C, et al. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs. 2018;78:1791\u2013804. https:\/\/doi.org\/10.1007\/s40265-018-0992-5.","journal-title":"Drugs"},{"key":"186_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/J.EPLEPSYRES.2019.03.015","volume":"154","author":"LC Laux","year":"2019","unstructured":"Laux LC, Bebin EM, Checketts D, Chez M, Flamini R, Marsh ED, et al. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or dravet syndrome: expanded access program results. Epilepsy Res. 2019;154:13\u201320. https:\/\/doi.org\/10.1016\/J.EPLEPSYRES.2019.03.015.","journal-title":"Epilepsy Res"},{"key":"186_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.5863\/1551-6776-27.6.558","volume":"27","author":"NT Cohen","year":"2022","unstructured":"Cohen NT, Bahar B, Conry JA, Schreiber JM. Variability in serum concentrations and clinical response in artisanal versus pharmaceutical cannabidiol treatment of pediatric pharmacoresistant epilepsy. J Pediatr Pharmacol Ther. 2022;27:558\u201363. https:\/\/doi.org\/10.5863\/1551-6776-27.6.558.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"68","key":"186_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1590\/1806-9282.2022D689","volume":"2022","author":"A Silvinato","year":"1992","unstructured":"Silvinato A, Floriano I, Bernardo WM. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Rev Assoc Med Bras. 1992;2022(68):1345\u201357. https:\/\/doi.org\/10.1590\/1806-9282.2022D689.","journal-title":"Rev Assoc Med Bras"},{"key":"186_CR10","doi-asserted-by":"publisher","first-page":"109159","DOI":"10.1016\/j.yebeh.2023.109159","volume":"141","author":"D Georgieva","year":"2023","unstructured":"Georgieva D, Langley J, Hartkopf K, Hawk L, Margolis A, Struck A, et al. Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex\u00ae (cannabidiol) in patients with refractory epilepsy. Epilepsy Behav. 2023;141:109159.","journal-title":"Epilepsy Behav"},{"key":"186_CR11","doi-asserted-by":"publisher","first-page":"614811","DOI":"10.3389\/fphar.2021.614811","volume":"12","author":"FM Leweke","year":"2021","unstructured":"Leweke FM, Rohleder C, Gerth CW, Hellmich M, Pukrop R, Koethe D. Cannabidiol and amisulpride improve cognition in acute schizophrenia in an explorative, double-blind, active-controlled, randomized clinical trial. Front Pharmacol. 2021;12:614811.","journal-title":"Front Pharmacol"},{"issue":"3","key":"186_CR12","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2(3):e94.","journal-title":"Transl Psychiatry"},{"issue":"3","key":"186_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018;175(3):225\u201331. https:\/\/doi.org\/10.1176\/appi.ajp.2017.17030325.","journal-title":"Am J Psychiatry"},{"key":"186_CR14","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291719003519","author":"A O\u2019Neill","year":"2020","unstructured":"O\u2019Neill A, Wilson R, Blest-Hopley G, Annibale L, Colizzi M, Brammer M, et al. Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis. Psychol Med. 2020. https:\/\/doi.org\/10.1017\/S0033291719003519.","journal-title":"Psychol Med"},{"key":"186_CR15","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2018.2309","volume":"75","author":"S Bhattacharyya","year":"2018","unstructured":"Bhattacharyya S, Wilson R, Appiah-Kusi E, O\u2019Neill A, Brammer M, Perez J, et al. Effect of cannabidiol on medial temporal, midbrain, and Striatal Dysfunction in people at clinical high risk of psychosis: a Randomized Clinical Trial. JAMA Psychiatry. 2018;75:1107\u201317. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.2309.","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"186_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/S41398-020-0862-2","volume":"10","author":"C Davies","year":"2020","unstructured":"Davies C, Wilson R, Appiah-Kusi E, Blest-Hopley G, Brammer M, Perez J, et al. A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis. Transl Psychiatry. 2020;10(1):311. https:\/\/doi.org\/10.1038\/S41398-020-0862-2.","journal-title":"Transl Psychiatry"},{"issue":"1","key":"186_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/S41398-019-0534-2","volume":"9","author":"R Wilson","year":"2019","unstructured":"Wilson R, Bossong MG, Appiah-Kusi E, Petros N, Brammer M, Perez J, et al. Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis. Transl Psychiatry. 2019;9(1):203. https:\/\/doi.org\/10.1038\/S41398-019-0534-2.","journal-title":"Transl Psychiatry"},{"key":"186_CR18","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00213-019-05442-6","volume":"237","author":"E Appiah-Kusi","year":"2020","unstructured":"Appiah-Kusi E, Petros N, Wilson R, Colizzi M, Bossong MG, Valmaggia L, et al. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology. 2020;237:1121\u201330. https:\/\/doi.org\/10.1007\/s00213-019-05442-6.","journal-title":"Psychopharmacology"},{"key":"186_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1590\/1516-4446-2021-2317","volume":"44","author":"LM Bolsoni","year":"2022","unstructured":"Bolsoni LM, Crippa JAS, Hallak JEC, Guimaraes FS, Zuardi AW. The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event. Braz J Psychiatry. 2022;44:298\u2013307. https:\/\/doi.org\/10.1590\/1516-4446-2021-2317.","journal-title":"Braz J Psychiatry"},{"key":"186_CR20","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/S00213-021-06043-Y","volume":"239","author":"LM Bolsoni","year":"2022","unstructured":"Bolsoni LM, Crippa JAS, Hallak JEC, Guimar\u00e3es FS, Zuardi AW. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder. Psychopharmacology. 2022;239:1499\u2013507. https:\/\/doi.org\/10.1007\/S00213-021-06043-Y.","journal-title":"Psychopharmacology"},{"issue":"8","key":"186_CR21","doi-asserted-by":"publisher","first-page":"e2120603","DOI":"10.1001\/jamanetworkopen.2021.20603","volume":"4","author":"JAS Crippa","year":"2021","unstructured":"Crippa JAS, Zuardi AW, Guimar\u00e3es FS, Campos AC, de Lima Os\u00f3rio F, Loureiro SR, et al. Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and burnout among frontline health care workers during the COVID-19 pandemic: a randomized clinical trial. JAMA Netw Open. 2021;4(8):e2120603.","journal-title":"JAMA Netw Open"},{"key":"186_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/0269881119895536","volume":"34","author":"SM de Faria","year":"2020","unstructured":"de Faria SM, de Morais Fabr\u00edcio D, Tumas V, Castro PC, Ponti MA, Hallak JEC, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a simulated public speaking test in patients with Parkinson\u2019s disease. J Psychopharmacol. 2020;34:189\u201396. https:\/\/doi.org\/10.1177\/0269881119895536.","journal-title":"J Psychopharmacol"},{"key":"186_CR23","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/MDS.28577","volume":"36","author":"CMO de Almeida","year":"2021","unstructured":"de Almeida CMO, Brito MMC, Bosaipo NB, Pimentel A v., Tumas V, Zuardi AW, et al. Cannabidiol for rapid eye movement sleep behavior disorder. Mov Disord. 2021;36:1711\u20135. https:\/\/doi.org\/10.1002\/MDS.28577.","journal-title":"Mov Disord"},{"key":"186_CR24","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881114550355","volume":"28","author":"MHN Chagas","year":"2014","unstructured":"Chagas MHN, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, et al. Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: an exploratory double-blind trial. J Psychopharmacol. 2014;28:1088\u201392. https:\/\/doi.org\/10.1177\/0269881114550355.","journal-title":"J Psychopharmacol"},{"key":"186_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","volume":"25","author":"JAS Crippa","year":"2011","unstructured":"Crippa JAS, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FLS, Martin-Santos R, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011;25:121\u201330. https:\/\/doi.org\/10.1177\/0269881110379283.","journal-title":"J Psychopharmacol"},{"key":"186_CR26","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","volume":"36","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, Queiroz RHC, Chagas MHN, de Oliveira DCG, de Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-nave social phobia patients. Neuropsychopharmacology. 2011;36:1219\u201326. https:\/\/doi.org\/10.1038\/npp.2011.6.","journal-title":"Neuropsychopharmacology"},{"key":"186_CR27","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3389\/fpsyg.2019.02466","volume":"10","author":"N Masataka","year":"2019","unstructured":"Masataka N. Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Front Psychol. 2019;10:2466. https:\/\/doi.org\/10.3389\/fpsyg.2019.02466.","journal-title":"Front Psychol"},{"key":"186_CR28","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/S41386-019-0333-8","volume":"44","author":"CM Pretzsch","year":"2019","unstructured":"Pretzsch CM, Freyberg J, Voinescu B, Lythgoe D, Horder J, Mendez MA, et al. Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology. 2019;44:1398\u2013405. https:\/\/doi.org\/10.1038\/S41386-019-0333-8.","journal-title":"Neuropsychopharmacology"},{"key":"186_CR29","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1177\/0269881119858306","volume":"33","author":"CM Pretzsch","year":"2019","unstructured":"Pretzsch CM, Voinescu B, Mendez MA, Wichers R, Ajram L, Ivin G, et al. The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). J Psychopharmacol. 2019;33:1141\u20138. https:\/\/doi.org\/10.1177\/0269881119858306.","journal-title":"J Psychopharmacol"},{"key":"186_CR30","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/bcp.14399","volume":"87","author":"D Efron","year":"2021","unstructured":"Efron D, Freeman JL, Cranswick N, Payne JM, Mulraney M, Prakash C, et al. A pilot randomised placebo-controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability. Br J Clin Pharmacol. 2021;87:436\u201346. https:\/\/doi.org\/10.1111\/bcp.14399.","journal-title":"Br J Clin Pharmacol"},{"issue":"S1","key":"186_CR31","doi-asserted-by":"publisher","first-page":"417S","DOI":"10.1002\/J.1552-4604.1981.TB02622.X","volume":"21","author":"EA Carlini","year":"1981","unstructured":"Carlini EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol. 1981;21(S1):417S-427S. https:\/\/doi.org\/10.1002\/J.1552-4604.1981.TB02622.X.","journal-title":"J Clin Pharmacol"},{"key":"186_CR32","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jhsa.2022.03.002","volume":"47","author":"JT Heineman","year":"2022","unstructured":"Heineman JT, Forster GL, Stephens KL, Cottler PS, Timko MP, DeGeorge BR. A randomized controlled trial of topical cannabidiol for the treatment of thumb basal joint arthritis. J Hand Surg. 2022;47:611\u201320. https:\/\/doi.org\/10.1016\/j.jhsa.2022.03.002.","journal-title":"J Hand Surg"},{"key":"186_CR33","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2174\/1389201020666191202111534","volume":"21","author":"DH Xu","year":"2019","unstructured":"Xu DH, Cullen BD, Tang M, Fang Y. The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. Curr Pharm Biotechnol. 2019;21:390\u2013402. https:\/\/doi.org\/10.2174\/1389201020666191202111534.","journal-title":"Curr Pharm Biotechnol"},{"key":"186_CR34","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","volume":"176","author":"YL Hurd","year":"2019","unstructured":"Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, et al. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry. 2019;176:911\u201322. https:\/\/doi.org\/10.1176\/appi.ajp.2019.18101191.","journal-title":"Am J Psychiatry"},{"key":"186_CR35","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1038\/S41386-021-01098-Z","volume":"46","author":"F Morissette","year":"2021","unstructured":"Morissette F, Mongeau-P\u00e9russe V, Rizkallah E, Th\u00e9bault P, Lepage S, Brissette S, et al. Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trial. Neuropsychopharmacology. 2021;46:2101\u201311. https:\/\/doi.org\/10.1038\/S41386-021-01098-Z.","journal-title":"Neuropsychopharmacology"},{"key":"186_CR36","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","volume":"7","author":"TP Freeman","year":"2020","unstructured":"Freeman TP, Hindocha C, Baio G, Shaban NDC, Thomas EM, Astbury D, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive bayesian trial. Lancet Psychiatry. 2020;7:865\u201374. https:\/\/doi.org\/10.1016\/S2215-0366(20)30290-X.","journal-title":"Lancet Psychiatry"},{"key":"186_CR37","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1111\/ADD.14243","volume":"113","author":"C Hindocha","year":"2018","unstructured":"Hindocha C, Freeman TP, Grabski M, Stroud JB, Crudgington H, Davies AC, et al. Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. Addiction (Abingdon England). 2018;113:1696. https:\/\/doi.org\/10.1111\/ADD.14243.","journal-title":"Addiction (Abingdon England)"},{"key":"186_CR38","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/J.ADDBEH.2013.03.011","volume":"38","author":"CJA Morgan","year":"2013","unstructured":"Morgan CJA, Das RK, Joye A, Curran HV, Kamboj SK. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav. 2013;38:2433\u20136. https:\/\/doi.org\/10.1016\/J.ADDBEH.2013.03.011.","journal-title":"Addict Behav"},{"key":"186_CR39","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF00432554","volume":"76","author":"AW Zuardi","year":"1982","unstructured":"Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology. 1982;76:245\u201350. https:\/\/doi.org\/10.1007\/BF00432554.","journal-title":"Psychopharmacology"},{"key":"186_CR40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/0014-2999(74)90129-0","volume":"28","author":"IG Karniol","year":"1974","unstructured":"Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA. Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. Eur J Pharmacol. 1974;28:172\u20137. https:\/\/doi.org\/10.1016\/0014-2999(74)90129-0.","journal-title":"Eur J Pharmacol"},{"key":"186_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","volume":"41","author":"IM Linares","year":"2019","unstructured":"Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimar\u00e3es FS, et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry. 2019;41:9\u201314. https:\/\/doi.org\/10.1590\/1516-4446-2017-0015.","journal-title":"Braz J Psychiatry"},{"key":"186_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fphar.2017.00259","volume":"8","author":"AW Zuardi","year":"2017","unstructured":"Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimar\u00e3es FS, et al. Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol. 2017;8:259. https:\/\/doi.org\/10.3389\/fphar.2017.00259.","journal-title":"Front Pharmacol"},{"key":"186_CR43","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/026988119300700112","volume":"7","author":"AW Zuardi","year":"1993","unstructured":"Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol. 1993;7:82\u20138. https:\/\/doi.org\/10.1177\/026988119300700112.","journal-title":"J Psychopharmacol"},{"key":"186_CR44","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00213-012-2955-y","volume":"226","author":"RK Das","year":"2013","unstructured":"Das RK, Kamboj SK, Ramadas M, Yogan K, Gupta V, Redman E, et al. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology. 2013;226:781\u201392. https:\/\/doi.org\/10.1007\/s00213-012-2955-y.","journal-title":"Psychopharmacology"},{"key":"186_CR45","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/SJ.NPP.1300340","volume":"29","author":"JA de Souza Crippa","year":"2004","unstructured":"de Souza Crippa JA, Zuardi AW, Garrido GEJ, Wichert-Ana L, Guarnieri R, Ferrari L, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology. 2004;29:417\u201326. https:\/\/doi.org\/10.1038\/SJ.NPP.1300340.","journal-title":"Neuropsychopharmacology"},{"key":"186_CR46","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1017\/S1461145709990617","volume":"13","author":"P Fusar-Poli","year":"2010","unstructured":"Fusar-Poli P, Allen P, Bhattacharyya S, Crippa JA, Mechelli A, Borgwardt S, et al. Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol. 2010;13:421\u201332. https:\/\/doi.org\/10.1017\/S1461145709990617.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"12","key":"186_CR47","doi-asserted-by":"publisher","first-page":"e93760","DOI":"10.1172\/jci.insight.93760","volume":"2","author":"KA Jadoon","year":"2017","unstructured":"Jadoon KA, Tan GD, O\u2019Sullivan SE. A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI Insight. 2017;2(12):e93760.","journal-title":"JCI Insight"},{"issue":"6","key":"186_CR48","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/ibd\/izz017","volume":"25","author":"DG Couch","year":"2019","unstructured":"Couch DG, Cook H, Ortori C, Barrett D, Lund JN, O\u2019Sullivan SE. Palmitoylethanolamide and cannabidiol prevent inflammation-induced hyperpermeability of the human gut in vitro and in vivo-a randomized, placebo-controlled, double-blind controlled trial. Inflamm Bowel Dis. 2019;25(6):1006\u201318. https:\/\/doi.org\/10.1093\/ibd\/izz017.","journal-title":"Inflamm Bowel Dis"},{"key":"186_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14225","author":"SR Sultan","year":"2020","unstructured":"Sultan SR, O\u2019Sullivan SE, England TJ. The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: a randomised controlled trial. Br J Clin Pharmacol. 2020. https:\/\/doi.org\/10.1111\/bcp.14225.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"186_CR50","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.3390\/IJMS22094876","volume":"22","author":"RM Vitale","year":"2021","unstructured":"Vitale RM, Iannotti FA, Amodeo P. The (poly)pharmacology of cannabidiol in neurological and neuropsychiatric disorders: molecular mechanisms and targets. Int J Mol Sci. 2021;22(9):4876. https:\/\/doi.org\/10.3390\/IJMS22094876.","journal-title":"Int J Mol Sci"},{"key":"186_CR51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1089\/CAN.2020.0102","volume":"6","author":"SE O\u2019Sullivan","year":"2021","unstructured":"O\u2019Sullivan SE, Stevenson CW, Laviolette SR. Could cannabidiol be a treatment for coronavirus disease-19-related anxiety disorders? Cannabis Cannabinoid Res. 2021;6:7\u201318. https:\/\/doi.org\/10.1089\/CAN.2020.0102.","journal-title":"Cannabis Cannabinoid Res"},{"key":"186_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s40211-020-00334-0","author":"C Laczkovics","year":"2020","unstructured":"Laczkovics C, Kothgassner OD, Felnhofer A, Klier CM. Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression. Neuropsychiatrie. 2020. https:\/\/doi.org\/10.1007\/s40211-020-00334-0.","journal-title":"Neuropsychiatrie"},{"key":"186_CR53","doi-asserted-by":"publisher","first-page":"e235307","DOI":"10.1136\/BCR-2020-235307","volume":"13","author":"M Berger","year":"2020","unstructured":"Berger M, Li E, Amminger GP. Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol. BMJ Case Reports CP. 2020;13:e235307. https:\/\/doi.org\/10.1136\/BCR-2020-235307.","journal-title":"BMJ Case Reports CP"},{"key":"186_CR54","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/JCPT.12018","volume":"38","author":"JAS Crippa","year":"2013","unstructured":"Crippa JAS, Hallak JEC, Machado-De-Sousa JP, Queiroz RHC, Bergamaschi M, Chagas MHN, et al. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. J Clin Pharm Ther. 2013;38:162\u20134. https:\/\/doi.org\/10.1111\/JCPT.12018.","journal-title":"J Clin Pharm Ther"},{"key":"186_CR55","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/JCP.0000000000001152","volume":"40","author":"CM Klier","year":"2020","unstructured":"Klier CM, de Gier C, Felnhofer A, Laczkovics C, Amminger PG. A case report of cannabidiol treatment of a Crohn\u2019s disease patient with anxiety disorder. J Clin Psychopharmacol. 2020;40:90\u20132. https:\/\/doi.org\/10.1097\/JCP.0000000000001152.","journal-title":"J Clin Psychopharmacol"},{"key":"186_CR56","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpopen20x101010","author":"G Gulbransen","year":"2020","unstructured":"Gulbransen G, Xu W, Arroll B. Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP Open. 2020. https:\/\/doi.org\/10.3399\/bjgpopen20x101010. :bjgpopen20X101010.","journal-title":"BJGP Open"},{"key":"186_CR57","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7812\/TPP\/18-041","volume":"23","author":"S Shannon","year":"2019","unstructured":"Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in anxiety and sleep: a large case series. Perm J. 2019;23:18\u2013041. https:\/\/doi.org\/10.7812\/TPP\/18-041.","journal-title":"Perm J"},{"issue":"5","key":"186_CR58","doi-asserted-by":"publisher","first-page":"21m14130","DOI":"10.4088\/JCP.21M14130","volume":"83","author":"M Berger","year":"2022","unstructured":"Berger M, Li E, Rice S, Davey CG, Ratheesh A, Adams S, et al. Cannabidiol for treatment-resistant anxiety disorders in young people: an open-label trial. J Clin Psychiatry. 2022;83(5):21m14130. https:\/\/doi.org\/10.4088\/JCP.21M14130.","journal-title":"J Clin Psychiatry"},{"key":"186_CR59","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archgenpsychiatry.2008.519","volume":"66","author":"P Fusar-Poli","year":"2009","unstructured":"Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009;66:95\u2013105. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2008.519.","journal-title":"Arch Gen Psychiatry"},{"key":"186_CR60","doi-asserted-by":"publisher","DOI":"10.1089\/CAN.2022.0062","author":"TB Stanley","year":"2022","unstructured":"Stanley TB, Ferretti ML, Bonn-Miller MO, Irons JG, Double-Blind A. Randomized, placebo-controlled test of the effects of cannabidiol on experiences of test anxiety among college students. Cannabis Cannabinoid Res. 2022. https:\/\/doi.org\/10.1089\/CAN.2022.0062.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"12","key":"186_CR61","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1177\/02698811221125440","volume":"36","author":"D Fabris","year":"2022","unstructured":"Fabris D, Carvalho MC, Brand\u00e3o ML, Prado WA, Zuardi AW, Crippa JA, et al. Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze. J Psychopharmacol. 2022;36(12):1371\u201383. https:\/\/doi.org\/10.1177\/02698811221125440.","journal-title":"J Psychopharmacol"},{"key":"186_CR62","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/S00213-022-06070-3","volume":"239","author":"MAP Bloomfield","year":"2022","unstructured":"Bloomfield MAP, Yamamori Y, Hindocha C, Jones APM, Yim JLL, Walker HR, et al. The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study. Psychopharmacology. 2022;239:1539\u201349. https:\/\/doi.org\/10.1007\/S00213-022-06070-3.","journal-title":"Psychopharmacology"},{"key":"186_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/S00213-022-06258-7","author":"EW Leen-Feldner","year":"2022","unstructured":"Leen-Feldner EW, Bynion TM, Eglit GML, Bonn-Miller MO, Gournay LR, Feldner MT. A double-blind, randomized, placebo-controlled test of the effects of cannabidiol on fear elicited by a 10% carbon dioxide-enriched air breathing challenge. Psychopharmacology. 2022. https:\/\/doi.org\/10.1007\/S00213-022-06258-7.","journal-title":"Psychopharmacology"},{"key":"186_CR64","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/0269881117737400","volume":"32","author":"H Hundal","year":"2018","unstructured":"Hundal H, Lister R, Evans N, Antley A, Englund A, Murray RM, et al. The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group. J Psychopharmacol. 2018;32:276\u201382. https:\/\/doi.org\/10.1177\/0269881117737400.","journal-title":"J Psychopharmacol"},{"key":"186_CR65","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1590\/1516-4446-2020-1416","volume":"43","author":"C de Meneses-Gaya","year":"2021","unstructured":"de Meneses-Gaya C, Crippa JA, Hallak JE, Miguel AQ, Laranjeira R, Bressan RA, et al. Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study. Braz J Psychiatry. 2021;43:467\u201376. https:\/\/doi.org\/10.1590\/1516-4446-2020-1416.","journal-title":"Braz J Psychiatry"},{"key":"186_CR66","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/J.EURONEURO.2022.04.003","volume":"59","author":"CM Kwee","year":"2022","unstructured":"Kwee CM, Baas JM, van der Flier FE, Groenink L, Duits P, Eikelenboom M, et al. Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: a randomised controlled trial. Eur Neuropsychopharmacol. 2022;59:58\u201367. https:\/\/doi.org\/10.1016\/J.EURONEURO.2022.04.003.","journal-title":"Eur Neuropsychopharmacol"},{"key":"186_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom10111575","volume":"10","author":"MS Garc\u00eda-Guti\u00e9rrez","year":"2020","unstructured":"Garc\u00eda-Guti\u00e9rrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J, Cannabidiol. A potential new alternative for the treatment of anxiety, depression, and psychotic disorders. Biomolecules. 2020;10:1\u201334. https:\/\/doi.org\/10.3390\/biom10111575.","journal-title":"Biomolecules"},{"key":"186_CR68","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/bs.pmbts.2019.06.005","volume":"167","author":"S Elsaid","year":"2019","unstructured":"Elsaid S, Kloiber S, le Foll B. Effects of cannabidiol (CBD) in neuropsychiatric disorders: a review of pre-clinical and clinical findings. Prog Mol Biol Transl Sci. 2019;167:25\u201375. https:\/\/doi.org\/10.1016\/bs.pmbts.2019.06.005.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"186_CR69","doi-asserted-by":"publisher","first-page":"204512531988191","DOI":"10.1177\/2045125319881916","volume":"9","author":"C Davies","year":"2019","unstructured":"Davies C, Bhattacharyya S. Cannabidiol as a potential treatment for psychosis. Ther Adv Psychopharmacol. 2019;9:204512531988191. https:\/\/doi.org\/10.1177\/2045125319881916.","journal-title":"Ther Adv Psychopharmacol"},{"key":"186_CR70","unstructured":"Zuardi A, Morais SL, Guimar\u00e3es F, Mechoulam R. Antipsychotic effect of cannabidiol. Undefined 1995."},{"key":"186_CR71","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1177\/0269881106060967","volume":"20","author":"AW Zuardi","year":"2006","unstructured":"Zuardi AW, Hallak JEC, Dursun SM, Morais SL, Sanches RF, Musty RE, et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol. 2006;20:683\u20136. https:\/\/doi.org\/10.1177\/0269881106060967.","journal-title":"J Psychopharmacol"},{"key":"186_CR72","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/0269881108096521","volume":"24","author":"AW Zuardi","year":"2010","unstructured":"Zuardi AW, Crippa JAS, Dursun SM, Morais SL, Vilela JAA, Sanches RF, et al. Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol. 2010;24:135\u20137. https:\/\/doi.org\/10.1177\/0269881108096521.","journal-title":"J Psychopharmacol"},{"key":"186_CR73","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1590\/S1516-44462010000100011","volume":"32","author":"JEC Hallak","year":"2010","unstructured":"Hallak JEC, Machado-de-Sousa JP, Crippa JAS, Sanches RF, Trzesniak C, Chaves C, et al. Performance of schizophrenic patients in the stroop color word test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Braz J Psychiatry. 2010;32:56\u201361. https:\/\/doi.org\/10.1590\/S1516-44462010000100011.","journal-title":"Braz J Psychiatry"},{"key":"186_CR74","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1017\/S0033291719003519","volume":"51","author":"A O\u2019Neill","year":"2021","unstructured":"O\u2019Neill A, Wilson R, Blest-Hopley G, Annibale L, Colizzi M, Brammer M, et al. Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis. Psychol Med. 2021;51:596\u2013606. https:\/\/doi.org\/10.1017\/S0033291719003519.","journal-title":"Psychol Med"},{"key":"186_CR75","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.3390\/PHARMACEUTICS14122598","volume":"14","author":"JDR Souza","year":"2022","unstructured":"Souza JDR, Pacheco JC, Rossi GN, de-Paulo BO, Zuardi AW, Guimar\u00e3es FS, et al. Adverse Effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020\u20132022). Pharmaceutics. 2022;14:2598. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14122598.","journal-title":"Pharmaceutics"},{"key":"186_CR76","doi-asserted-by":"publisher","first-page":"113440","DOI":"10.1016\/J.BBR.2021.113440","volume":"412","author":"S Vaseghi","year":"2021","unstructured":"Vaseghi S, Arjmandi-Rad S, Nasehi M, Zarrindast MR. Cannabinoids and sleep-wake cycle: the potential role of serotonin. Behav Brain Res. 2021;412:113440. https:\/\/doi.org\/10.1016\/J.BBR.2021.113440.","journal-title":"Behav Brain Res"},{"key":"186_CR77","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/J.CHEST.2022.04.151","volume":"162","author":"I Lavender","year":"2022","unstructured":"Lavender I, McGregor IS, Suraev A, Grunstein RR, Hoyos CM. Cannabinoids, insomnia, and other sleep disorders. Chest. 2022;162:452\u201365. https:\/\/doi.org\/10.1016\/J.CHEST.2022.04.151.","journal-title":"Chest"},{"key":"186_CR78","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/S40263-021-00867-0","volume":"35","author":"KA Klotz","year":"2021","unstructured":"Klotz KA, Grob D, Sch\u00f6nberger J, Nakamura L, Metternich B, Schulze-Bonhage A, et al. Effect of cannabidiol on interictal epileptiform activity and sleep architecture in children with intractable epilepsy: a prospective open-label study. CNS Drugs. 2021;35:1207\u201315. https:\/\/doi.org\/10.1007\/S40263-021-00867-0.","journal-title":"CNS Drugs"},{"key":"186_CR79","doi-asserted-by":"publisher","first-page":"108325","DOI":"10.1016\/j.yebeh.2021.108325","volume":"124","author":"CL Anderson","year":"2021","unstructured":"Anderson CL, Evans V, Gorham L, Liu Z, Johnson CR, Carney PR. Seizure frequency, quality of life, behavior, cognition, and sleep in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. Epilepsy Behav. 2021;124:108325.","journal-title":"Epilepsy Behav"},{"key":"186_CR80","doi-asserted-by":"publisher","first-page":"16","DOI":"10.7812\/TPP\/16-005","volume":"20","author":"S Shannon","year":"2016","unstructured":"Shannon S, Opila-Lehman J. Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report. Perm J. 2016;20:16\u2013005. https:\/\/doi.org\/10.7812\/TPP\/16-005.","journal-title":"Perm J"},{"key":"186_CR81","first-page":"31","volume":"14","author":"S Shannon","year":"2015","unstructured":"Shannon S, Opila-Lehman J. Cannabidiol Oil for decreasing addictive use of marijuana: a case report. Integr Med (Encinitas). 2015;14:31\u20135.","journal-title":"Integr Med (Encinitas)"},{"key":"186_CR82","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/JCPT.12179","volume":"39","author":"MHN Chagas","year":"2014","unstructured":"Chagas MHN, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson\u2019s disease patients: a case series. J Clin Pharm Ther. 2014;39:564\u20136. https:\/\/doi.org\/10.1111\/JCPT.12179.","journal-title":"J Clin Pharm Ther"},{"key":"186_CR83","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/FPHAR.2018.00315","volume":"9","author":"IMP Linares","year":"2018","unstructured":"Linares IMP, Guimaraes FS, Eckeli A, Crippa ACS, Zuardi AW, Souza JDS, et al. No acute effects of cannabidiol on the sleep-wake cycle of healthy subjects: a randomized, double-blind, placebo-controlled, crossover study. Front Pharmacol. 2018;9:315. https:\/\/doi.org\/10.3389\/FPHAR.2018.00315.","journal-title":"Front Pharmacol"},{"key":"186_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21228870","volume":"21","author":"J Mlost","year":"2020","unstructured":"Mlost J, Bryk M, Starowicz K. Cannabidiol for pain treatment: focus on pharmacology and mechanism of action. Int J Mol Sci. 2020;21:1\u201322. https:\/\/doi.org\/10.3390\/ijms21228870.","journal-title":"Int J Mol Sci"},{"key":"186_CR85","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/FBP.0000000000000119","volume":"26","author":"H Neelakantan","year":"2015","unstructured":"Neelakantan H, Tallarida RJ, Reichenbach ZW, Tuma RF, Ward SJ, Walker EA. Distinct interactions of cannabidiol and morphine in three nociceptive behavioral models in mice. Behav Pharmacol. 2015;26:304\u201314. https:\/\/doi.org\/10.1097\/FBP.0000000000000119.","journal-title":"Behav Pharmacol"},{"key":"186_CR86","doi-asserted-by":"publisher","first-page":"114076","DOI":"10.1016\/j.bbr.2022.114076","volume":"435","author":"CHA Jesus","year":"2022","unstructured":"Jesus CHA, Ferreira MV, Gasparin AT, Rosa ES, Genaro K, de Souza Crippa JA. Cannabidiol enhances the antinociceptive effects of morphine and attenuates opioid-induced tolerance in the chronic constriction injury model. Behav Brain Res. 2022;435:114076.","journal-title":"Behav Brain Res"},{"key":"186_CR87","doi-asserted-by":"publisher","first-page":"9441","DOI":"10.1007\/S00520-022-07312-Y","volume":"30","author":"SW Nielsen","year":"2022","unstructured":"Nielsen SW, Hasselsteen SD, Dominiak HSH, Labudovic D, Reiter L, Dalton SO, et al. Oral cannabidiol for prevention of acute and transient chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2022;30:9441\u201351. https:\/\/doi.org\/10.1007\/S00520-022-07312-Y.","journal-title":"Support Care Cancer"},{"key":"186_CR88","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/bcp.14973","volume":"88","author":"CA Arout","year":"2022","unstructured":"Arout CA, Haney M, Herrmann ES, Bedi G, Cooper ZD. A placebo-controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans. Br J Clin Pharmacol. 2022;88:347\u201355. https:\/\/doi.org\/10.1111\/bcp.14973.","journal-title":"Br J Clin Pharmacol"},{"key":"186_CR89","doi-asserted-by":"publisher","first-page":"E62","DOI":"10.1097\/j.pain.0000000000002310","volume":"163","author":"T Schneider","year":"2022","unstructured":"Schneider T, Zurbriggen L, Dieterle M, Mauermann E, Frei P, Mercer-Chalmers-Bender K, et al. Pain response to cannabidiol in induced acute nociceptive pain, allodynia, and hyperalgesia by using a model mimicking acute pain in healthy adults in a randomized trial (CANAB I). Pain. 2022;163:E62\u201371. https:\/\/doi.org\/10.1097\/j.pain.0000000000002310.","journal-title":"Pain"},{"key":"186_CR90","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1249\/MSS.0000000000002606","volume":"53","author":"KC Cochrane-Snyman","year":"2021","unstructured":"Cochrane-Snyman KC, Cruz C, Morales J, Coles M. The effects of cannabidiol oil on noninvasive measures of muscle damage in men. Med Sci Sports Exerc. 2021;53:1460\u201372. https:\/\/doi.org\/10.1249\/MSS.0000000000002606.","journal-title":"Med Sci Sports Exerc"},{"key":"186_CR91","doi-asserted-by":"publisher","first-page":"370","DOI":"10.5694\/mja2.51014","volume":"214","author":"B Bebee","year":"2021","unstructured":"Bebee B, Taylor DM, Bourke E, Pollack K, Foster L, Ching M, et al. The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain. Med J Aust. 2021;214:370\u20135. https:\/\/doi.org\/10.5694\/mja2.51014.","journal-title":"Med J Aust"},{"key":"186_CR92","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1097\/j.pain.0000000000002466","volume":"163","author":"J Vela","year":"2022","unstructured":"Vela J, Dreyer L, Petersen KK, Arendt-Nielsen L, Duch KS, Kristensen S. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Pain. 2022;163:1206\u201314. https:\/\/doi.org\/10.1097\/j.pain.0000000000002466.","journal-title":"Pain"},{"key":"186_CR93","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3389\/FPHAR.2018.00482","volume":"9","author":"FF Peres","year":"2018","unstructured":"Peres FF, Lima AC, Hallak JEC, Crippa JA, Silva RH, Ab\u00edlio VC. Cannabidiol as a promising strategy to treat and prevent movement disorders? Front Pharmacol. 2018;9:482. https:\/\/doi.org\/10.3389\/FPHAR.2018.00482.","journal-title":"Front Pharmacol"},{"key":"186_CR94","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3109\/00207458608985678","volume":"30","author":"P Consroe","year":"1986","unstructured":"Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci. 1986;30:277\u201382. https:\/\/doi.org\/10.3109\/00207458608985678.","journal-title":"Int J Neurosci"},{"key":"186_CR95","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/0269881108096519","volume":"23","author":"AW Zuardi","year":"2009","unstructured":"Zuardi AW, Crippa JAS, Hallak JEC, Pinto JP, Chagas MHN, Rodrigues GGR, et al. Cannabidiol for the treatment of psychosis in Parkinson\u2019s disease. J Psychopharmacol. 2009;23:979\u201383. https:\/\/doi.org\/10.1177\/0269881108096519.","journal-title":"J Psychopharmacol"},{"key":"186_CR96","doi-asserted-by":"publisher","DOI":"10.1089\/CAN.2021.0158","author":"CMO de Almeida","year":"2022","unstructured":"de Almeida CMO, Brito MMC, Bosaipo NB, Pimentel AV, Sobreira-Neto MA, Tumas V, et al. The effect of cannabidiol for restless legs syndrome\/Willis-Ekbom disease in Parkinson\u2019s disease patients with REM sleep behavior disorder: a post hoc exploratory analysis of phase 2\/3 clinical trial. Cannabis Cannabinoid Res. 2022. https:\/\/doi.org\/10.1089\/CAN.2021.0158.","journal-title":"Cannabis Cannabinoid Res"},{"key":"186_CR97","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","volume":"40","author":"P Consroe","year":"1991","unstructured":"Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, et al. Controlled clinical trial of cannabidiol in Huntington\u2019s disease. Pharmacol Biochem Behav. 1991;40:701\u20138. https:\/\/doi.org\/10.1016\/0091-3057(91)90386-G.","journal-title":"Pharmacol Biochem Behav"},{"key":"186_CR98","doi-asserted-by":"publisher","first-page":"694510","DOI":"10.3389\/fphar.2021.694510","volume":"12","author":"A Gasparyan","year":"2021","unstructured":"Gasparyan A, Navarrete F, Manzanares J. Cannabidiol and sertraline regulate behavioral and brain gene expression alterations in an animal model of PTSD. Front Pharmacol. 2021;12:694510.","journal-title":"Front Pharmacol"},{"key":"186_CR99","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1089\/acm.2018.0437","volume":"25","author":"L Elms","year":"2019","unstructured":"Elms L, Shannon S, Hughes S, Lewis N. Cannabidiol in the treatment of post-traumatic stress disorder: a case series. J Altern Complement Med. 2019;25:392\u20137. https:\/\/doi.org\/10.1089\/acm.2018.0437.","journal-title":"J Altern Complement Med"},{"key":"186_CR100","doi-asserted-by":"publisher","first-page":"108","DOI":"10.7812\/TPP\/16-005","volume":"20","author":"S Shannon","year":"2016","unstructured":"Shannon S, Opila-Lehman J. Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report. Perm J. 2016;20:108\u201311. https:\/\/doi.org\/10.7812\/TPP\/16-005.","journal-title":"Perm J"},{"key":"186_CR101","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/S00213-022-06132-6","volume":"239","author":"X Han","year":"2022","unstructured":"Han X, Song X, Song D, Xie G, Guo H, Wu N, et al. Comparison between cannabidiol and sertraline for the modulation of post-traumatic stress disorder-like behaviors and fear memory in mice. Psychopharmacology. 2022;239:1605\u201320. https:\/\/doi.org\/10.1007\/S00213-022-06132-6.","journal-title":"Psychopharmacology"},{"key":"186_CR102","doi-asserted-by":"publisher","first-page":"18.300.","DOI":"10.7812\/TPP\/18.300","volume":"23","author":"LM Bolsoni","year":"2019","unstructured":"Bolsoni LM, da Silva TDA, Quintana SM, de Castro M, Crippa JA, Zuardi AW. Changes in cortisol awakening response before and after development of posttraumatic stress disorder, which cannot be avoided with use of cannabidiol: a case report. Perm J. 2019;23:18.300. https:\/\/doi.org\/10.7812\/TPP\/18.300.","journal-title":"Perm J"},{"key":"186_CR103","doi-asserted-by":"publisher","first-page":"856846","DOI":"10.3389\/fphar.2022.856846","volume":"13","author":"JDS Souza","year":"2022","unstructured":"Souza JDS, Zuardi AW, Guimar\u00e3es FS, Os\u00f3rio F, de Loureiro L, Campos SR. Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic. Front Pharmacol. 2022;13:856846.","journal-title":"Front Pharmacol"},{"key":"186_CR104","doi-asserted-by":"publisher","first-page":"107360","DOI":"10.1016\/j.addbeh.2022.107360","volume":"132","author":"V Paulus","year":"2022","unstructured":"Paulus V, Billieux J, Benyamina A, Karila L. Cannabidiol in the context of substance use disorder treatment: a systematic review. Addict Behav. 2022;132:107360.","journal-title":"Addict Behav"},{"key":"186_CR105","doi-asserted-by":"publisher","first-page":"899221","DOI":"10.3389\/fpsyt.2022.899221","volume":"13","author":"G Cleirec","year":"2022","unstructured":"Cleirec G, Desmier E, Lacatus C, Lesgourgues S, Braun A, Peloso C, et al. Efficiency of inhaled cannabidiol in cannabis use disorder: the pilot study Cannavap. Front Psychiatry. 2022;13:899221.","journal-title":"Front Psychiatry"},{"key":"186_CR106","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1111\/ADD.15417","volume":"116","author":"V Mongeau-P\u00e9russe","year":"2021","unstructured":"Mongeau-P\u00e9russe V, Brissette S, Bruneau J, Conrod P, Dubreucq S, Gazil G, et al. Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo-controlled trial. Addiction (Abingdon England). 2021;116:2431\u201342. https:\/\/doi.org\/10.1111\/ADD.15417.","journal-title":"Addiction (Abingdon England)"},{"issue":"9","key":"186_CR107","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.3390\/IJMS21093067","volume":"21","author":"V Mart\u00ednez","year":"2020","unstructured":"Mart\u00ednez V, Iriondo De-Hond A, Borrelli F, Capasso R, del Castillo MD, Abalo R. Cannabidiol and other non-psychoactive cannabinoids for prevention and treatment of gastrointestinal disorders: useful nutraceuticals? Int J Mol Sci. 2020;21(9):3067. https:\/\/doi.org\/10.3390\/IJMS21093067.","journal-title":"Int J Mol Sci"},{"key":"186_CR108","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/IBD\/IZY014","volume":"24","author":"DG Couch","year":"2018","unstructured":"Couch DG, Maudslay H, Doleman B, Lund JN, O\u2019Sullivan SE. The use of cannabinoids in colitis: a systematic review and Meta-analysis. Inflamm Bowel Dis. 2018;24:680\u201397. https:\/\/doi.org\/10.1093\/IBD\/IZY014.","journal-title":"Inflamm Bowel Dis"},{"key":"186_CR109","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s10620-017-4540-z","volume":"62","author":"T Naftali","year":"2017","unstructured":"Naftali T, Mechulam R, Marii A, Gabay G, Stein A, Bronshtain M, et al. Low-dose cannabidiol is safe but not effective in the treatment for Crohn\u2019s disease, a randomized controlled trial. Dig Dis Sci. 2017;62:1615\u201320. https:\/\/doi.org\/10.1007\/s10620-017-4540-z.","journal-title":"Dig Dis Sci"},{"key":"186_CR110","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.14309\/AJG.0000000000001805","volume":"117","author":"J Atieh","year":"2022","unstructured":"Atieh J, Maselli D, Breen-Lyles M, Torres M, Katzka D, Ryks M, et al. Cannabidiol for functional dyspepsia with normal gastric emptying: a randomized controlled trial. Am J Gastroenterol. 2022;117:1296\u2013304. https:\/\/doi.org\/10.14309\/AJG.0000000000001805.","journal-title":"Am J Gastroenterol"},{"key":"186_CR111","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1089\/CAN.2020.0087","volume":"7","author":"A-CB van Orten-Luiten","year":"2022","unstructured":"van Orten-Luiten A-CB, de Roos NM, Majait S, Witteman BJM, Witkamp RF. Effects of cannabidiol chewing gum on perceived pain and well-being of irritable bowel syndrome patients: a placebo-controlled crossover exploratory intervention study with Symptom-Driven Dosing. Cannabis Cannabinoid Res. 2022;7:436\u201344. https:\/\/doi.org\/10.1089\/CAN.2020.0087.","journal-title":"Cannabis Cannabinoid Res"},{"key":"186_CR112","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/S00213-022-06196-4","volume":"239","author":"JFC Pedrazzi","year":"2022","unstructured":"Pedrazzi JFC, Ferreira FR, Silva-Amaral D, Lima DA, Hallak JEC, Zuardi AW, et al. Cannabidiol for the treatment of autism spectrum disorder: hope or hype? Psychopharmacology. 2022;239:2713\u201334. https:\/\/doi.org\/10.1007\/S00213-022-06196-4.","journal-title":"Psychopharmacology"},{"key":"186_CR113","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/J.PNPBP.2018.08.030","volume":"89","author":"S Poleg","year":"2019","unstructured":"Poleg S, Golubchik P, Offen D, Weizman A. Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2019;89:90\u20136. https:\/\/doi.org\/10.1016\/J.PNPBP.2018.08.030.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"186_CR114","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1365-2125.2012.04351.x","volume":"75","author":"CP Stanley","year":"2013","unstructured":"Stanley CP, Hind WH, O\u2019Sullivan SE. Is the cardiovascular system a therapeutic target for cannabidiol? Br J Clin Pharmacol. 2013;75:313\u201322. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04351.x.","journal-title":"Br J Clin Pharmacol"},{"key":"186_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/IJMS21186740","volume":"21","author":"A Kicman","year":"2020","unstructured":"Kicman A, Toczek M. The Effects of Cannabidiol, a non-intoxicating compound of cannabis, on the cardiovascular system in health and disease. Int J Mol Sci. 2020;21:1\u201345. https:\/\/doi.org\/10.3390\/IJMS21186740.","journal-title":"Int J Mol Sci"},{"key":"186_CR116","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3389\/fphar.2017.00081","volume":"8","author":"SR Sultan","year":"2017","unstructured":"Sultan SR, Millar SA, England TJ, O\u2019Sullivan SE. A systematic review and meta-analysis of the haemodynamic effects of cannabidiol. Front Pharmacol. 2017;8:81. https:\/\/doi.org\/10.3389\/fphar.2017.00081.","journal-title":"Front Pharmacol"},{"issue":"7","key":"186_CR117","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3390\/JPM12071037","volume":"12","author":"M Kumric","year":"2022","unstructured":"Kumric M, Bozic J, Dujic G, Vrdoljak J, Dujic Z. Chronic effects of effective oral cannabidiol delivery on 24-h ambulatory blood pressure and vascular outcomes in treated and untreated hypertension (HYPER-H21-4): study protocol for a randomized, placebo-controlled, and crossover study. J Pers Med. 2022;12(7):1037. https:\/\/doi.org\/10.3390\/JPM12071037.","journal-title":"J Pers Med"},{"key":"186_CR118","doi-asserted-by":"publisher","first-page":"110728","DOI":"10.1016\/j.biopha.2020.110728","volume":"132","author":"S Pagano","year":"2020","unstructured":"Pagano S, Coniglio M, Valenti C, Federici MI, Lombardo G, Cianetti S, et al. Biological effects of cannabidiol on normal human healthy cell populations: systematic review of the literature. Biomed Pharmacother. 2020;132:110728.","journal-title":"Biomed Pharmacother"},{"key":"186_CR119","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3389\/FONC.2018.00643\/BIBTEX","volume":"9","author":"PB Dall\u2019Stella","year":"2019","unstructured":"Dall\u2019Stella PB, Docema MFL, Maldaun MVC, Feher O, Lancellotti CLP. Case report: clinical outcome and image response of two patients with secondary high-grade glioma treated with chemoradiation, PCV, and cannabidiol. Front Oncol. 2019;9:643. https:\/\/doi.org\/10.3389\/FONC.2018.00643\/BIBTEX.","journal-title":"Front Oncol"},{"key":"186_CR120","doi-asserted-by":"publisher","first-page":"77","DOI":"10.21873\/CDP.10011","volume":"1","author":"R LIKAR","year":"2021","unstructured":"LIKAR R, KOESTENBERGER M, STUTSCHNIG M. Cannabidiol \u039cay prolong survival in patients with Glioblastoma Multiforme. Cancer Diagn Progn. 2021;1:77. https:\/\/doi.org\/10.21873\/CDP.10011.","journal-title":"Cancer Diagn Progn"},{"key":"186_CR121","doi-asserted-by":"publisher","first-page":"5831","DOI":"10.21873\/ANTICANRES.12924","volume":"38","author":"J Kenyon","year":"2018","unstructured":"Kenyon J, Liu W, Dalgleish A. Report of Objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. Anticancer Res. 2018;38:5831\u20135. https:\/\/doi.org\/10.21873\/ANTICANRES.12924.","journal-title":"Anticancer Res"},{"key":"186_CR122","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/J.NEUROPHARM.2007.06.029","volume":"54","author":"L Weiss","year":"2008","unstructured":"Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, et al. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology. 2008;54:244\u20139. https:\/\/doi.org\/10.1016\/J.NEUROPHARM.2007.06.029.","journal-title":"Neuropharmacology"},{"key":"186_CR123","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3233\/CH-168021","volume":"64","author":"C Lehmann","year":"2016","unstructured":"Lehmann C, Fisher NB, Tugwell B, Szczesniak A, Kelly M, Zhou J. Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes. Clin Hemorheol Microcirc. 2016;64:655\u201362. https:\/\/doi.org\/10.3233\/CH-168021.","journal-title":"Clin Hemorheol Microcirc"},{"key":"186_CR124","doi-asserted-by":"publisher","first-page":"108819","DOI":"10.1016\/j.cbi.2019.108819","volume":"312","author":"MRT Zorzenon","year":"2019","unstructured":"Zorzenon MRT, Santiago AN, Mori MA, Piovan S, Jansen CA, Perina Padilha ME, et al. Cannabidiol improves metabolic dysfunction in middle-aged diabetic rats submitted to a chronic cerebral hypoperfusion. Chem Biol Interact. 2019;312:108819.","journal-title":"Chem Biol Interact"},{"key":"186_CR125","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/J.BRAINRES.2019.03.014","volume":"1715","author":"CHA Jesus","year":"2019","unstructured":"Jesus CHA, Redivo DDB, Gasparin AT, Sotomaior BB, de Carvalho MC, Genaro K, et al. Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors. Brain Res. 2019;1715:156\u201364. https:\/\/doi.org\/10.1016\/J.BRAINRES.2019.03.014.","journal-title":"Brain Res"},{"key":"186_CR126","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/S12640-018-9972-5","volume":"35","author":"AN Santiago","year":"2019","unstructured":"Santiago AN, Mori MA, Guimar\u00e3es FS, Milani H, Weffort de Oliveira RM. Effects of cannabidiol on diabetes outcomes and chronic cerebral hypoperfusion comorbidities in middle-aged rats. Neurotox Res. 2019;35:463\u201374. https:\/\/doi.org\/10.1007\/S12640-018-9972-5.","journal-title":"Neurotox Res"},{"key":"186_CR127","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.2337\/dc16-0650","volume":"39","author":"KA Jadoon","year":"2016","unstructured":"Jadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD, et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care. 2016;39:1777\u201386. https:\/\/doi.org\/10.2337\/dc16-0650.","journal-title":"Diabetes Care"},{"key":"186_CR128","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/J.BBMT.2015.05.018","volume":"21","author":"M Yeshurun","year":"2015","unstructured":"Yeshurun M, Shpilberg O, Herscovici C, Shargian L, Dreyer J, Peck A, et al. Cannabidiol for the prevention of graft-versus-host-disease after allogeneic hematopoietic cell transplantation: results of a phase II study. Biol Blood Marrow Transplant. 2015;21:1770\u20135. https:\/\/doi.org\/10.1016\/J.BBMT.2015.05.018.","journal-title":"Biol Blood Marrow Transplant"},{"key":"186_CR129","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/J.SURVOPHTHAL.2020.07.002","volume":"66","author":"MTM Wang","year":"2021","unstructured":"Wang MTM, Danesh-Meyer H. v. Cannabinoids and the eye. Surv Ophthalmol. 2021;66:327\u201345. https:\/\/doi.org\/10.1016\/J.SURVOPHTHAL.2020.07.002.","journal-title":"Surv Ophthalmol"},{"key":"186_CR130","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/01.IJG.0000212260.04488.60","volume":"15","author":"I Tomida","year":"2006","unstructured":"Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma. 2006;15:349\u201353. https:\/\/doi.org\/10.1097\/01.IJG.0000212260.04488.60.","journal-title":"J Glaucoma"},{"key":"186_CR131","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00841-6","author":"B Tayo","year":"2019","unstructured":"Tayo B, Taylor L, Sahebkar F, Morrison GA, Phase I, Open-Label P-G. Single-dose trial of the pharmacokinetics, safety, and tolerability of cannabidiol in subjects with mild to severe renal impairment. Clin Pharmacokinet. 2019. https:\/\/doi.org\/10.1007\/s40262-019-00841-6.","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Cannabis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-023-00186-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42238-023-00186-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-023-00186-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T20:36:10Z","timestamp":1686688570000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcannabisresearch.biomedcentral.com\/articles\/10.1186\/s42238-023-00186-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":131,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["186"],"URL":"https:\/\/doi.org\/10.1186\/s42238-023-00186-9","relation":{},"ISSN":["2522-5782"],"issn-type":[{"value":"2522-5782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"assertion":[{"value":"2 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Saoirse Elizabeth O\u2019Sullivan is a paid consultant to Vectura Fertin Pharma, Switzerland, and a paid employee of Artelo Biosceince, USA. Sanne Skov Jensen<sup>,<\/sup> Gitte Nykj\u00e6r Nikolajsen and Heidi Ziegler Bruun are paid employees of Fertin Pharma, Denmark. Rhenu Bhuller and Julia Hoeng are paid employees of Vectura Fertin Pharma, Switzerland.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}